Phase II Trial of Neutron Radiotherapy With Concurrent Checkpoint Inhibitor Immunotherapy (Pembrolizumab) in Patients With Advanced Urothelial Carcinoma
Phase of Trial: Phase II
Latest Information Update: 17 May 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- 25 Feb 2019 Status changed from not yet recruiting to recruiting.
- 14 Jan 2019 Planned initiation date changed from 1 Jan 2019 to 14 Feb 2019.
- 09 Nov 2018 Planned initiation date changed from 1 Jun 2018 to 1 Jan 2019.